Impact of HAART therapy on cognitive function in patients with HIV: a systematic review of randomized control trial

Read full text Summarise with VIRAT
Authors: Mohammad Al Diab Al Azzawi, Arina Mohammed Alhamed, Hind M Almajed, Wejdan Abdat, Norah Nasser A Alshahrani, Ibhar S. Idris, Omar Aldayhani, Fadwa Fallatah, Rawan Hamdi Bedaiwi
Cited by: 0
References: 24

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Cognitive impairment remains common in adults with HIV despite effective viral suppression on combination antiretroviral therapy. We systematically reviewed randomized trials evaluating the impact of different regimens or intensification strategies on cognitive outcomes. Methods: Following PRISMA, we searched PubMed, Scopus, Cochrane Library, and Web of Science from inception to 5 September 2025 for randomized controlled trials in adults that compared cognitive outcomes between combination antiretroviral regimens, placebo or no intensification. Eligible trials reported neuropsychological or cognitive test results. Risk of bias was assessed with the Cochrane ROB 2 tool. Owing to heterogeneity of cognitive measures, data were synthesized narratively. Results: Six trials (721 participants) met the criteria. Three evaluated initial regimens in antiretroviral-naïve participants and three tested maraviroc (MVC)- or dolutegravir-based intensification in virally suppressed individuals with neurocognitive impairment. Outcomes included global composite scores and domain-specific measures of memory, attention, executive function, processing/psychomotor speed, and motor function. Within-arm improvements were generally small; only one small pilot trial reported moderate cognitive benefit with MVC intensification. Larger trials did not show significant advantages of alternative or intensified regimens over standard therapy. Safety profiles were similar between arms. Conclusion: Available randomized evidence does not demonstrate a consistent additional cognitive benefit of alternative or intensified combination antiretroviral regimens beyond standard therapy with viral suppression. Given the small number and size of trials, modest regimen-specific effects in subgroups cannot be excluded. Future studies should use larger samples, harmonized outcome measures, and evaluate multimodal interventions combining optimized antiretroviral therapy with adjunctive pharmacological and non-pharmacological approaches.

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV Research and Treatment HIV-related health complications and treatments

Publication details

Journal / source
Annals of Medicine and Surgery
Volume
88
Issue
4
Pages
2599–2609
Publication date
18 March 2026
Language
EN